STLN Starling Oncology, Inc.
Services-Offices & Clinics of Doctors of Medicine · Nasdaq · SEC CIK 1799191 · Fiscal year ends 12/31
Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY21.7%
TTM net income YoY5.6%
TTM EPS YoY16.9%
Revenue 3-yr CAGR25.5%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-8.9%
Net margin-14.4%
FCF margin-6.0%
EBITDA margin-7.4%
Returns
ROE-4,132.2%
ROA-38.7%
ROIC (approx.)-67.7%
Asset turnover2.69x
Leverage & solvency
Liabilities / assets107.5%
Debt / equity—
Current ratio1.68x
Interest coverage-3.90x
Cash quality & payout
Operating cash flow / net income0.36x
Accruals ratio-24.8%
Payout ratio—
Capex / revenue0.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $502.73M | $393.41M |
| SG&A expense | $105.57M | $107.83M |
| Operating income | -$36.08M | -$60.12M |
| Interest expense | $11.28M | $7.50M |
| Pretax income | -$60.74M | -$64.66M |
| Income tax | -$131,000 | $0 |
| Net income | -$60.61M | -$64.66M |
| EBITDA | -$29.14M | -$53.83M |
| EPS (basic) | -0.54 | -0.71 |
| EPS (diluted) | -0.54 | -0.71 |
| Weighted avg. shares (diluted) | 92.39M | 75.04M |
| Balance sheet | ||
| Cash & equivalents | $33.56M | $49.67M |
| Short-term investments | — | $0 |
| Receivables | $59.00M | $48.34M |
| Inventory | $16.88M | $10.04M |
| Current assets | $112.75M | $112.42M |
| PP&E, net | $10.68M | $11.89M |
| Goodwill | $7.23M | $7.23M |
| Intangibles | $11.02M | $14.81M |
| Total assets | $164.66M | $172.72M |
| Current liabilities | $70.96M | $52.22M |
| Long-term debt | $77.40M | $93.13M |
| Total debt | $77.40M | $93.13M |
| Total liabilities | $180.38M | $169.13M |
| Shareholders' equity | -$15.72M | $3.59M |
| Net debt | $43.84M | $43.46M |
| Shares outstanding | 98.86M | 75.74M |
| Cash flow statement | ||
| Operating cash flow | -$24.59M | -$26.54M |
| Capital expenditure | $3.20M | $3.79M |
| Free cash flow | -$27.79M | -$30.33M |
| Investing cash flow | -$3.07M | $46.21M |
| Financing cash flow | $11.56M | -$3.49M |
| Depreciation & amortization | $6.94M | $6.29M |
| Stock-based compensation | $4.55M | $11.15M |
| Share buybacks | — | $0 |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.